Steer Clear of Viberzi in Patients Who Don't Have a Gallbladder
May 2017
FDA is now warning to avoid Viberzi (eluxadoline) in patients who don't have a gallbladder.
This is due to an increased risk of serious pancreatitis that can result in hospitalization or death in these patients.
You've likely seen ads promoting Viberzi for irritable bowel syndrome with diarrhea. It's an opioid agonist that works primarily in the gut at usual doses...similar to loperamide (Imodium A-D, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote